BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

Kyle Blankenship

BeiGene blazed the trail for a growing wave of Chinese oncology drugs breaking through in the US with an initial approval for BTK inhibitor Brukinsa …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

Kyle Blankenship

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

BeiGene looks to carve out more space in the US mar­ket, set­ting up BTK drug for 2nd blood can­cer nod

Kyle Blankenship

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus